Pall GMP corrections must be certified by outside consultant -- FDA warning letter.
This article was originally published in The Gray Sheet
Executive Summary
PALL CORP. PROCEDURES FOR DETERMINING "SIGNIFICANT" PROCESS CHANGES should be established in written documents, FDA says in a Feb. 2 warning letter to the company. During a Dec. 4-14 inspection of the firm's Fajardo, Puerto Rico facility, FDA inspectors found that there was not "any procedure that defined, or described by example, what constitutes a `significant' change" to manufacturing process or materials, the letter says.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.